Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall
Suite 400
San Diego,
CA 92121
United States - Map
Phone: 858-587-9333
Fax: 858-558-6470
Web Site: http://www.holliseden.com
| Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine. The company was founded in 1992 and is headquartered in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. James M. Frincke Ph.D, 58
Chief Exec. Officer, Pres, Chief Operating Officer |
N/A
| N/A | Mr. Robert W. Weber , 58
Interim Chief Financial Officer, Chief Accounting Officer, VP of Operations and Controller |
$
235.00K |
$
28.00K | Dr. Dwight R. Stickney M.D, 66
Chief Medical Officer |
N/A
| N/A | Dr. Christopher L. Reading Ph.D, 61
Chief Scientific Officer |
N/A
| N/A | Mr. Robert L. Marsella , 56
Sr. VP of Bus. Devel. and Marketing |
$
248.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.03% Nasdaq 
Profile
